LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

NCT04032080 | Completed Phase 2 Results FDA Drug

• 1 other identifier: 018-745
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.

Conditions

Triple Negative Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Efficacy (Objective Response Rate)

  To assess the objective response rate associated with LY3023414 and prexasertib in metastatic TNBC patients. Objective response is measured as prolonged clinical benefit; clinical benefit is defined as progression free survival on study therapy for at least 6 months.

  Through study completion, approximately 2 years and 8 months

Secondary Outcomes (1)

• Efficacy (Duration of Response)

  From the time that 6 months of progression free survival on study therapy was first met until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year.

Study Arms (1)

LY3023414 + prexasertib

EXPERIMENTAL

Patients with metastatic TNBC who meet the enrollment criteria will receive LY3023414 and prexasertib until disease progression. Patients whose disease does not respond to the combination of LY3023414 and prexasertib may be treated with standard of care breast cancer therapies off study, at the recommendation of the treating physician.

Combination Product: Drug 1: LY3023414; Drug 2: Prexasertib

Interventions

Drug 1: LY3023414; Drug 2: Prexasertib COMBINATION_PRODUCT

Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry. Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m\^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted. Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses.

LY3023414 + prexasertib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients ≥18 years of age. Patients must agree to use one highly effective (less than 1% failure rate) method of contraception or use a combination of two effective methods of contraception during treatment with study drug and for at least 12 weeks following the last dose of study drug.
• Have a diagnosis of metastatic TNBC previously treated with standard anthracycline, cyclophosphamide, and taxane chemotherapy, unless there was a contraindication to doxorubicin, in which case prior treatment with this agent is not required. NOTE: TNBC defined as ER-negative tumors with ≤10% tumor nuclei immunoreactivity, or "ER Low Positive" as defined by the updated ASCO/CAP guidelines 2020.
• Have not received more than 3 prior chemotherapy regimens for metastatic disease. Prior platinum and/or taxane therapy in the adjuvant or metastatic setting is permitted.
• Have locoregional (eg, breast, chest wall, regional lymphatic) or pulmonary or hepatic metastatic disease that is amenable to core needle biopsy. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted. If a skin biopsy cannot be safely obtained, patients may still be eligible, per physician discretion.
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Have adequate hematologic function, defined by:
• Absolute neutrophil count (ANC) \>1500/mm\^3
• Platelet count ≥100,000/mm\^3
• Hemoglobin ≥9 g/dL
• Have adequate liver function, defined by:
• AST and ALT ≤2.5 x the upper limit of normal (ULN) or ≤5 x ULN in presence of liver metastases
• Total bilirubin ≤1.5 x ULN
• Have adequate renal function, defined by:
• a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥60 ml/min
• Have the ability to swallow oral medications

You may not qualify if:

• Have a family history of long QT Syndrome and serious cardiac conditions.
• Have QTcF interval of \>470 msec on screening electrocardiogram (ECG) as well as on pre-dose Cycle 1 Day 1 ECG
• Have insulin-dependent diabetes mellitus. Patients with a type 2 diabetes mellitus are eligible if adequate control of blood glucose level is obtained by oral anti-diabetics as documented by HbA1c \<8%. Patients with type 1 diabetes mellitus are not eligible.
• Previous radiotherapy for metastatic disease completed \<2 weeks prior to study treatment initiation.
• Women who are pregnant or lactating.
• Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as:
• severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air
• liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C).
• viral hepatitis or HIV.
• Concurrent use of CYP3A4 inhibitors and inducers from 72 hours prior to initiation of study treatment until the end of treatment.
• History of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or that might affect interpretation of the results of this study, or render the patient at high risk for treatment complications.
• Patients who have received prior PI3K or CHK therapy.
• Any other investigational or anti-cancer treatments while participating in this study
• Any other active malignancy.

Sponsors & Collaborators

• Baylor Research Institute: lead
• Eli Lilly and Company: collaborator

Study Sites (1)

Baylor University Medical Center

Dallas, Texas, 75246, United States

Location

MeSH Terms

Conditions

Triple Negative Breast Neoplasms

Condition Hierarchy (Ancestors)

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Results Point of Contact

• Title: Joyce O'Shaughnessy, MD
• Organization: Baylor Scott & White Health

joyce.oshaughnessy@usoncology.com

214-818-8472

Study Officials

• Joyce A O'Shaughnessy, MD

  Baylor Scott and White University Medical Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Patients with metastatic TNBC who meet the enrollment criteria will receive LY3023414 and prexasertib until disease progression.

Study Record Dates

• First Submitted: July 23, 2019
• First Posted: July 25, 2019
• Study Start: September 5, 2019
• Primary Completion: June 1, 2022
• Study Completion: November 26, 2022
• Last Updated: September 11, 2023
• Results First Posted: September 11, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)